SITAGLIPTIN DIN 02545535
Status: Approved
Holder: LABORATOIRE RIVA INC.
Health Canada record
| Active ingredient(s) | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A10BH01 SITAGLIPTIN |
| Original market date | |
| Current status date | 21-Feb-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Laboratoire Riva Inc. — licence 100179, currently licensed, last inspection rating C (2026-01-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02428261 | APO-SITAGLIPTIN | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG | Marketed |
| 02428296 | APO-SITAGLIPTIN | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG | Marketed |
| 02428288 | APO-SITAGLIPTIN | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG | Marketed |
| 02435799 | APO-SITAGLIPTIN-METFORMIN | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02435780 | APO-SITAGLIPTIN-METFORMIN | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02435772 | APO-SITAGLIPTIN-METFORMIN | APOTEX INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02506270 | APO-SITAGLIPTIN/METFORMIN XR | APOTEX INC | Tablet (Extended-Release) | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02506297 | APO-SITAGLIPTIN/METFORMIN XR | APOTEX INC | Tablet (Extended-Release) | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02506289 | APO-SITAGLIPTIN/METFORMIN XR | APOTEX INC | Tablet (Extended-Release) | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02333872 | JANUMET | MERCK CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02333856 | JANUMET | MERCK CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02416786 | JANUMET XR | MERCK CANADA INC | Tablet (Extended-Release) | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02416794 | JANUMET XR | MERCK CANADA INC | Tablet (Extended-Release) | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02416808 | JANUMET XR | MERCK CANADA INC | Tablet (Extended-Release) | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02303922 | JANUVIA | MERCK CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG | Marketed |
| 02388847 | JANUVIA | MERCK CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG | Marketed |
| 02388839 | JANUVIA | MERCK CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG | Marketed |
| 02535009 | M-SITAGLIPTIN | MANTRA PHARMA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG | Marketed |
| 02534983 | M-SITAGLIPTIN | MANTRA PHARMA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG | Marketed |
| 02534991 | M-SITAGLIPTIN | MANTRA PHARMA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG | Marketed |
| 02543400 | NAT-SITAGLIPTIN | NATCO PHARMA (CANADA) INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG | Marketed |
| 02503867 | PMS-SITAGLIPTIN | PHARMASCIENCE INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG | Marketed |
| 02503859 | PMS-SITAGLIPTIN | PHARMASCIENCE INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG | Marketed |
| 02503840 | PMS-SITAGLIPTIN | PHARMASCIENCE INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG | Marketed |
| 02552817 | PRO-SITAGLIPTIN-METFORMIN | PRO DOC LIMITEE | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02552825 | PRO-SITAGLIPTIN-METFORMIN | PRO DOC LIMITEE | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02545853 | PRZ-SITAGLIPTIN | PHARMARIS CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG | Marketed |
| 02545837 | PRZ-SITAGLIPTIN | PHARMARIS CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG | Marketed |
| 02545845 | PRZ-SITAGLIPTIN | PHARMARIS CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG | Marketed |
| 02552302 | PRZ-SITAGLIPTIN-METFORMIN | PHARMARIS CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Approved |
| 02552329 | PRZ-SITAGLIPTIN-METFORMIN | PHARMARIS CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02552310 | PRZ-SITAGLIPTIN-METFORMIN | PHARMARIS CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02545667 | RIVA SITAGLIPTIN/METFORMIN | LABORATOIRE RIVA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Approved |
| 02545675 | RIVA SITAGLIPTIN/METFORMIN | LABORATOIRE RIVA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Approved |
| 02504065 | SANDOZ SITAGLIPTIN | SANDOZ CANADA INCORPORATED | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG | Marketed |
| 02504057 | SANDOZ SITAGLIPTIN | SANDOZ CANADA INCORPORATED | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG | Marketed |
| 02504049 | SANDOZ SITAGLIPTIN | SANDOZ CANADA INCORPORATED | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG | Marketed |
| 02503964 | SANDOZ SITAGLIPTIN-METFORMIN | SANDOZ CANADA INCORPORATED | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02503956 | SANDOZ SITAGLIPTIN-METFORMIN | SANDOZ CANADA INCORPORATED | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02503972 | SANDOZ SITAGLIPTIN-METFORMIN | SANDOZ CANADA INCORPORATED | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02529106 | SANDOZ SITAGLIPTIN-METFORMIN XR | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02529122 | SANDOZ SITAGLIPTIN-METFORMIN XR | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02529114 | SANDOZ SITAGLIPTIN-METFORMIN XR | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02548550 | SITAGLIPTIN | SANIS HEALTH INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG | Marketed |
| 02529033 | SITAGLIPTIN | SIVEM PHARMACEUTICALS ULC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG | Marketed |
| 02529041 | SITAGLIPTIN | SIVEM PHARMACEUTICALS ULC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG | Marketed |
| 02529068 | SITAGLIPTIN | SIVEM PHARMACEUTICALS ULC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG | Marketed |
| 02545519 | SITAGLIPTIN | LABORATOIRE RIVA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG | Approved |
| 02545527 | SITAGLIPTIN | LABORATOIRE RIVA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG | Approved |
| 02548569 | SITAGLIPTIN | SANIS HEALTH INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG | Marketed |
| 02548577 | SITAGLIPTIN | SANIS HEALTH INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG | Marketed |
| 02529173 | SITAGLIPTIN-METFORMIN | SIVEM PHARMACEUTICALS ULC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02529165 | SITAGLIPTIN-METFORMIN | SIVEM PHARMACEUTICALS ULC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02529157 | SITAGLIPTIN-METFORMIN | SIVEM PHARMACEUTICALS ULC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02333864 | JANUMET | MERCK CANADA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Cancelled Post Market |
| 02532654 | PMS-SITAGLIPTIN-METFORMIN | PHARMASCIENCE INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Cancelled Pre Market |
| 02532662 | PMS-SITAGLIPTIN-METFORMIN | PHARMASCIENCE INC | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Cancelled Pre Market |
| 02526735 | RIVA SITAGLIPTIN | LABORATOIRE RIVA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG | Cancelled Pre Market |
| 02526727 | RIVA SITAGLIPTIN | LABORATOIRE RIVA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG | Cancelled Pre Market |
| 02526719 | RIVA SITAGLIPTIN | LABORATOIRE RIVA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32750 | 2024-02-21 | Abbreviated New Drug Submission (ANDS) | Administrative: Licensing Agreement Between Two Manufacturers |